AnaptysBio financials
$50.37−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M | $75.0M | $8.0M | $5.0M | $10.0M |
| Gross profit | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M | $75.0M | $8.0M | $5.0M | $10.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M | -$23.9M | -$107.4M | -$66.7M | -$28.8M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M | -$19.9M | -$97.3M | -$61.7M | -$30.1M |
| Net margin | −5.6% | −159.1% | −953.7% | −1251.3% | −91.5% | −26.6% | −1216.7% | −1233.1% | −300.7% |
| Diluted EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 | $-1.52 |
| EBITDA | $48.5M | -$114.3M | -$156.4M | -$114.5M | -$54.7M | -$23.3M | -$106.9M | -$66.4M | -$28.6M |
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M | -$14.2M | -$69.5M | -$48.5M | -$19.4M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M | -$14.7M | -$70.3M | -$49.6M | -$19.7M |
| Diluted shares | 28.8M | 28.4M | 26.9M | 28.2M | 27.4M | 27.3M | 27.1M | 24.7M | 19.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M | $250.5M |
| Short-term investments | $73.4M | $262.3M | $354.9M | $369.9M | $52.4M | $143.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M | $416.6M |
| Total liabilities | $327.2M | $413.0M | $364.3M | $348.3M | $286.6M | $19.8M |
| Shareholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M | $396.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology